International Clinical Trial: Phase 2b Study of a Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Protein Vaccine Candidate in Adults 60 Years of Age and Older

Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07810010) titled 'Phase 2b Study of a Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Protein Vaccine Candidate in Adults 60 Years of Age and Older' on Sept. 3.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).

Primary Sponsor: Sanofi

Condition: Respiratory Syncytial Virus Human Metapneumovirus Healthy Volunteers

Intervention: Biological: Bivalent RSV+HMPV protein vaccine

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollm...